TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Peanut Oral Immunotherapy in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical history of peanut allergy or avoidance of peanut without ever having eaten peanut;~* Serum immunoglobulin E (IgE) to peanut of ≥5 kUA/L determined by UniCAP™, an in-vitro test system for diagnosis and monitoring of allergy and inflammation;~* Wheal ≥ 3mm on skin prick test to peanut extract compared to a negative control;~* A clinical reaction at or below ingestion of 1 g peanut flour (500 mg peanut protein) during screening OFC;~* Written informed consent from parent/guardian.~Exclusion Criteria:~* History of severe anaphylaxis with hypotension to peanut;~* Documented clinical history of allergy to oat;~* Suspected allergy to oat and a wheal ≥7mm on skin prick test to oat extract compared to a negative control;~* Chronic disease other than asthma, atopic dermatitis, rhinitis requiring therapy; e.g., heart disease or diabetes;~* Active eosinophilic gastrointestinal disease in the past 2 years;~* Participation in any interventional study for the treatment of food allergy in the 6 months prior to visit -1;~* Inhalant allergen immunotherapy that has not yet reached maintenance dosing;~* Severe asthma, as indicated by repeated hospitalizations or hospital emergency department visits;~* Moderate asthma defined according to National Asthma Education and Prevention Program Expert;~* Panel that requires more than fluticasone 440 mcg or its equivalent daily for adequate control;~* Inability to discontinue antihistamines for skin testing, OFC and the initial dose escalation;~* Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) in the 12 months prior to visit -1;~* Any systemic therapy which in the judgment of the investigator could be immunomodulatory (e.g. rituximab) in the 12 months prior to visit -1, systemic corticosteroid therapy of up to a total of three weeks is allowed;~* Use of any investigational drug in 90 days prior to visit -1;~* Plan to use any investigational drug during the study period;~* The presence of any medical condition that the investigator deems incompatible with participation in the trial.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 48 Months
- Healthy Volunteers: f

Study Arms:
- Peanut Oral Immune Therapy (OIT) (Type: EXPERIMENTAL): Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
- Peanut Placebo (Type: PLACEBO_COMPARATOR): Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes who used Suglat Tablets within 3 months from its launch~Exclusion Criteria:~* off-label use patients

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suglat group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's written informed consent. Adequate cognitive capacity.~* Adequate family support~* No acute diverticulitis episode in the last 3 months~* mNeff 0 acute diverticulitis (abdominal computed tomography scan)~* No antibiotic treatment in the last 2 weeks~* Immunocompetence\*~* No significant comorbidities\*\*~* Good oral tolerance~* Good symptom control~* Maximum one of the following SIRS criteria (\* T\>38 ºC or \<36ºC, L\>12,000 or \<4000/uL, HR\>90 bpm, RR\<20 rpm) or CRP\>15 mg/dL~Exclusion Criteria:~* Women in pregnancy or breastfeeding~* Age \<18 years or \> 80 years.~* Absence of the patient's written informed consent. Inadequate cognitive capacity.~* Inadequate family support~* Acute diverticulitis episode in the last 3 months~* Moderate acute diverticulitis (mNeff grade I or upper)~* Antibiotic treatment in the last 2 weeks~* Inflammatory bowel disease~* Immunodepression\*~* Presence of significant comorbidities\*\*~* Bad oral tolerance~* Poor symptom control~* More than one of the following SIRS criteria (\* T\>38 ºC or \<36ºC, L\>12,000 or \<4000/uL, HR\>90 bpm, RR\<20 rpm) or CRP\>15 mg/dL~(\*) Immunocompetence is the absence and immunodepression is the presence of any of the following: active neoplastic disease/hematologic malignancy/HIV with low CD4+ count/long-term corticosteroid treatment/immunosuppressant therapy/transplant/splenectomy/genetic immunodeficiency.~(\*\*) We consider significant comorbidities any of the following: poorly controlled diabetes mellitus (HbA1\>7mg/dl), cardiologic event in the last 3 months, decompensation of hepatopathy in the last 3 months, renal chronic insufficiency in dialysis programme.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Symptomatic treatment with NSAID (Type: EXPERIMENTAL): 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
- Antibiotic+symptomatic treatment with NSAID (Type: ACTIVE_COMPARATOR): 875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age: 19-60 year-old women~* Plan of myomectomy for uterine leiomyomas~* Leiomyoma Subclassification System 2-7 (robot-assisted laparoscopic myomectomy is possible)~* American Society of Anesthesiologists Physical Status classification 1 or 2~* A person who understands the contents of the clinical trial, is cooperative with the trial, and is judged to be able to participate until the end of the study~Exclusion Criteria:~* Pregnancy or breastfeeding~* A single diameter of uterine leiomyoma is greater than 12 cm or more or multiple leiomyomas with more than five~* Suspicious disease of uterine malignancy~* Patient with has a history of pelvic surgery (cesarean section, myomectomy, etc.) and is expected to have severe pelvic adhesion~* A person who is hypersensitive or contraindicated to vasopressin~* A person who is hypersensitive or contraindicated to tranexamic acid~* Considered as inappropriate by the researcher's judgment

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Diluted Vasopressin Group 1 (Type: ACTIVE_COMPARATOR): During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 50 ml of normal saline to make a total of 100 ml) was injected before uterine serosal incision.
- Diluted Vasopressin Group 2 (Type: ACTIVE_COMPARATOR): During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 200 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.
- Diluted Vasopressin Group 3 (Type: ACTIVE_COMPARATOR): During robot-assisted laparoscopic myomectomy, diluted vasopressin (a solution prepared by mixing 20 units of vasopressin with 400 ml of normal saline to make a total of 100 m) was injected before uterine serosal incision.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~- Healthy male and female subjects~Exclusion criteria:~- Any relevant deviation from healthy condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Fixed dose combination (Type: EXPERIMENTAL): Single dose empagliflozin/metformin
- Single tablets combination (Type: ACTIVE_COMPARATOR): single doses empagliflozin and metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* healthy adults~* aged 25- 75 years~* with moderate to severe nasolabial folds~Exclusion Criteria:~* pregnant~* allergy to local anesthetics~* history of bleeding disorder~* active infection at the treatment site~* injectable filler in the nasolabial folds within past year

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- platelet rich fibrin matrix (Type: ACTIVE_COMPARATOR): Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.~Exclusion Criteria:~* Exclusion criteria must be read in conjunction with the local product information.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects between, and including, 18 and 45 years of age at the first vaccination;~2. Healthy subjects as established by medical history and history-oriented clinical examination;~3. Be able to understand and comply with the request of the protocol;~4. Without acute cervicitis;~5. Not pregnant;~6. Have intact cervix.~Exclusion Criteria:~1. Use of any investigational or non-registered product (drug or vaccine)within 30 days preceding the first vaccination, or plan to use during the study period;~2. Are using immunosuppressants;~3. Administration of immunoglobulin and/or any blood products within the three months preceding the first vaccination or planned administration during the study period;~4. Vaccinated of inactivated vaccine 14 days or attenuated vaccine 21 days before the enrollment;~5. Fever;~6. Concurrently participating another clinical trial;~7. Has received vaccines against HPV 16/18 ;~8. Immunodeficient;~9. History of allergic disease;~10. Serious medical disorders;~11. Blood coagulation disorders;~12. Epilepsy;~13. Unable to comply with protocol due to the mental illness;~14. Visible Condyloma;~15. Pregnant or breast-feeding women;~16. vergins;~17. Have more than 4 sexual partners.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HPV vaccine (Type: EXPERIMENTAL): This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
- HEV vaccine (Type: PLACEBO_COMPARATOR): commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Group 1 Inclusion Criteria:~* HIV-uninfected males or females age 18-50 years old~* Willing to maintain low risk behavior for HIV infection~Group 1 Exclusion Criteria:~* confirmed HIV-infection, pregnancy or lactation, significant acute or chronic disease and clinically significant laboratory abnormalities~Group 2 Inclusion Criteria:~* HIV-infected males or females age 18-65 years old~* On a stable antiretroviral regimen with HIV-1 RNA plasma level \<50 copies/ml, CD4 cell count greater than or equal to 300 cells/uL~Group 2 Exclusion Criteria:~* history of AIDS-defining illness within the previous 5 years, significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities~Group 3 Inclusion Criteria:~* HIV-infected males or females age 18-65~* Not on antiretroviral therapy for \> 6 months with detectable HIV-1 viral load between 100 and 100,000 copies/ml, CD4 cell count greater than or equal to 300 cells/uL~Group 3 Exclusion Criteria:~* history of AIDS-defining illness within the previous 5 years, significant acute or chronic medical condition other than HIV infection, and clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1A (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 1B (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 1C (Type: EXPERIMENTAL): HIV-uninfected participants
- Group 2A (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 2B (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 2C (Type: EXPERIMENTAL): HIV-infected on ART, (\<50 cp/ml)
- Group 3A (Type: EXPERIMENTAL): HIV-Infected off ART (VL 2x10\^3 - 1x10\^5 cp/ml)
- Group 3B (Type: EXPERIMENTAL): HIV-Infected off ART (VL 1x10\^2 - 2x10\^3 cp/ml)
- Arm 1D (Type: EXPERIMENTAL): HIV-uninfected participants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged \>=50 years~* Varicella history-positive or residence for \>30 years in a country with endemic VZV infection~Exclusion Criteria:~* Febrile illness~* History of hypersensitivity or anaphylactoid reaction to any of the vaccine components~* Prior herpes zoster episode clinically diagnosed or exposure to varicella or herpes zoster within the 4 weeks prior to vaccination~* Prior receipt of varicella or zoster vaccine~* Active untreated tuberculosis~* Thrombocytopenia, any other coagulation disorder contraindicating intramuscular injection~* Receipt of medication / vaccine that may interfere with study assessments~* Known or suspected immune dysfunction~* User of recreational / illicit drugs or subject with alcohol abuse or dependence within the last year~* Any condition that might interfere with the interpretation of the study,

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZOSTAVAX intramuscular (IM) route (Type: EXPERIMENTAL): Single dose of 0.65 mL via IM injection
- ZOSTAVAX subcutaneous (SC) route (Type: ACTIVE_COMPARATOR): Single dose of 0.65 mL via SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects.~* Non-dependent, recreational opioid users. (Must use opioid for non-therapeutic purposes on at least 10 occassions within the last year before Screening Visit, and at least once in 8 weeks before the Screening Visit.~Exclusion Criteria:~* Diagnosis of substance and/or alcohol dependence.~* Subject has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorder.~* History of sleep apnea.~* Positive urine drug screen (UDS) for other that marijuana.~* Positive for Hepatitis B or C and HIV on Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment D (Type: ACTIVE_COMPARATOR): None
- Treatment E (Type: EXPERIMENTAL): None
- Treatment F (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Chronically infected with HCV genotype 1~* Treatment naive or treatment non-responders or treatment intolerant~* HCV RNA viral load of ≥10\*5\* IU/mL~* BMI 18 to 35 kg/m²~Exclusion Criteria:~* Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with HCV infection~* Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug~* Co-infection with HIV or HBV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): BMS-791325 (100 mg)~or~placebo match for (100 mg)
- 2 (Type: EXPERIMENTAL): BMS-791325 (300 mg)~or~placebo match for (300 mg)
- 3 (Type: EXPERIMENTAL): BMS-791325 (900 mg)~or~placebo match for (900 mg)
- 4 (Type: EXPERIMENTAL): BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Mothers may be eligible for this study if they:~* Have been pregnant for more than 32 weeks and are at least 18 years of age.~* Are HIV-positive.~* Reside within 15 km of Mulago Hospital, the study site.~* Infants may be eligible for this study if they:~* Are born to mothers enrolled in the study.~* Have consent of the mother/guardian and, if available, the father.~Exclusion Criteria~Mothers will not be eligible for this study if they:~* Have a serious infection or illness other than HIV.~* Currently take any anti-HIV drugs.~* Participate during this pregnancy in another treatment vaccine perinatal trial.~* Received NVP or AZT within the last 6 months.~* Are allergic to any benzodiazepine.~* Abuse alcohol or other drugs.~* Have high blood pressure that is not controlled.~* Have received any anticoagulants, benzodiazepines other than the study drug, or magnesium sulfate within 2 weeks before being assigned to a study group or delivery.~* Infants will not be eligible for this study if:~* Their mother is excluded prior to being assigned to a study group.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete